Biomarker Usage Should Be Standardized Through FDA/NIH Collaboration
Executive Summary
A standardized approach for use of biomarkers in nonclinical studies should be established by FDA in collaboration with representatives from ongoing biomarker initiatives, the agency's Advisory Committee for Pharmaceutical Science/Nonclinical Studies Subcommittee concluded Dec. 14.